|
Pronunciation |
|
(poe
TASS ee um bye KAR bun ate &
poe TASS ee um SIT rate, ef er VES ent) |
|
|
U.S. Brand
Names |
|
Effer-K™; K-Ide®;
Klor-con®/EF; K-Lyte®; K-Vescent® |
|
|
Generic
Available |
|
No |
|
|
Synonyms |
|
Potassium Citrate and Potassium Bicarbonate, Effervescent |
|
|
Pharmacological Index |
|
Electrolyte Supplement, Oral |
|
|
Use |
|
Treatment or prevention of hypokalemia |
|
|
Pregnancy Risk
Factor |
|
C |
|
|
Contraindications |
|
Severe renal impairment, hyperkalemia |
|
|
Warnings/Precautions |
|
Use with caution in patients with renal disease, cardiac
disease |
|
|
Adverse
Reactions |
|
>10%: Gastrointestinal: Diarrhea, nausea, stomach pain, flatulence,
vomiting
1% to 10%:
Cardiovascular: Bradycardia
Endocrine & metabolic: Hyperkalemia
Local: Local tissue necrosis with extravasation
Neuromuscular & skeletal: Weakness
Respiratory: Dyspnea
<1%: Chest pain, mental confusion, alkalosis, abdominal pain, throat pain,
phlebitis, paresthesias, paralysis |
|
|
Overdosage/Toxicology |
|
Symptoms of overdose include muscle weakness, paralysis, peaked T waves,
flattened P waves, prolongation of QRS complex, ventricular arrhythmias
Removal of potassium can be accomplished by various means; removal through
the GI tract with Kayexalate® administration; by way of
the kidney through diuresis, mineralocorticoid administration or increased
sodium intake; by hemodialysis or peritoneal dialysis; or by shifting potassium
back into the cells by insulin and glucose infusion or sodium bicarbonate;
calcium chloride will reverse cardiac effects. |
|
|
Drug
Interactions |
|
Increased effect/levels with potassium-sparing diuretics, salt substitutes,
ACE inhibitors |
|
|
Mechanism of
Action |
|
Needed for the conduction of nerve impulses in heart, brain, and skeletal
muscle; contraction of cardiac, skeletal and smooth muscles; maintenance of
normal renal function |
|
|
Pharmacodynamics/Kinetics |
|
Absorption: Absorbed well from upper GI tract
Distribution: Enters cells via active transport from extracellular fluid
Elimination: Largely by the kidneys, but also small amount via the skin and
feces, with most intestinal potassium being reabsorbed |
|
|
Usual Dosage |
|
Oral:
Adults:
Prevention: 16-24 mEq/day in 2-4 divided doses
Treatment: 40-100 mEq/day in 2-4 divided doses |
|
|
Monitoring
Parameters |
|
Serum potassium |
|
|
Test
Interactions |
|
ammonia
(B) |
|
|
Dental Health: Local
Anesthetic/Vasoconstrictor
Precautions |
|
No information available to require special precautions |
|
|
Dental Health:
Effects on Dental Treatment |
|
No effects or complications reported |
|
|
Patient
Information |
|
Dissolve completely in 3-8 oz cold water, juice, or other suitable beverage
and drink slowly |
|
|
Nursing
Implications |
|
Monitor serum potassium |
|
|
Dosage Forms |
|
Capsule, extended release: 8 mEq, 10 mEq
Powder for oral solution: 15 mEq/packet; 20 mEq/packet; 25 mEq/packet
Tablet, effervescent: 25 mEq, 50 mEq
|
|
Copyright © 1978-2000 Lexi-Comp Inc. All Rights Reserved
|